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Abstract. 
Poor-quality medicines are a major problem for health-care systems in resource-poor settings as identifying 
falsified medicines requires a complex laboratory infrastructure such as a Medicines Quality Control 
Laboratory. We report here an evaluation of a low-cost, handheld near-infrared spectrometer (NIRS) device by 
analyzing a library of artemisinin-based combination therapy (ACT) medicines to determine its usefulness as a 
drug-screening tool. The “SCiO” research prototype device was used to collect NIR spectra of a library of ACT 
and artesunate monotherapy medicine samples previously collected in Bioko Island and Equatorial Guinea and 
Kintampo, Ghana. The quality of these samples had been categorized as falsified, substandard, and quality 
assured based on the amount of stated active pharmaceutical ingredients detected using high-performance liquid 
chromatography photodiode array. Numerical analyses were performed on the NIR spectra to assess the 
usefulness of NIR to identify falsified and substandard medicines. The NIRS device was successful at detecting 
falsified medicines in all cases where the library contained both quality assured and falsified medicines of the 
same stated brand of medicines. The NIRS device was successful at identifying substandard amounts of 
artesunate but not amodiaquine in the ACT samples (N = 15) of artesunate–amodiaquine. This work reveals that 
this low-cost, portable NIRS device is promising for screening ACTs for falsified samples and could enable 
widespread drug screening at all points of the health system. 
INTRODUCTION 
Drug quality is fundamental to the success of health interventions, with intentional or 
inadvertant provision of substandard and falsified medicines being a major contributor to 
delayed clinical recovery and mortality, particularly due to infectious disease in low-income 
countries.
1
 Use of medicines with subtherapeutic concentrations of the stated active 
pharmaceutical ingredient (SAPI) may drive microbial resistance. Although awareness of 
poor-quality medicines, in particular “fakes” has increased appreciably with the publication 
of reports citing that up to a third of antimalarials had failed chemical content analysis,
2,3
 the 
ability of health providers and consumers to detect substandard and falsified medication is 
limited by the high cost, limited accessibility, and destructive nature of testing. 
Medicine quality is commonly divided into four classes: quality assured, falsified (also 
referred to as counterfeit), substandard, and degraded.
4
 Quality-assured medicines have the 
specified amount of SAPI and meet other quality attributes. Falsified medicines do not 
contain the SAPIs indicated on the packaging and generally do not comply with intellectual 
property rights.
5
 Substandard medicines are produced with poor constituents or 
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manufacturing practice and may have contents or dissolution times that are outside of 
therapeutic limits,
6,7
 or have deteriorated due to adverse environmental conditions. Degraded 
formulations are commonly the result of exposure to light, heat, and/or humidity. It is clearly 
important to distinguish degraded from substandard products, as implications for rectifying 
these conditions are very different.
8
 In countries with insecure public or private supply 
chains, there is a need to detect at the point of importation as well as down the distribution 
chain to the point of purchase. Arguably, a place for consumer-level testing also exists in 
more regulated markets, where mail order medication (medicines bought over the internet) is 
becoming common practice. 
Detecting the quality of medicines is a challenge for health-care professionals even 
though strategies and specifications have been formalized by international organizations such 
as the U.S. Pharmacopeia, the World Health Organization (WHO), and the Global Fund. 
Testing predominantly requires a well-equipped Medicines Quality Control Laboratory 
(MQCL) equipped with a range of analytical equipment such as high-performance liquid 
chromatography photodiode array (HPLC-PDA), mass spectrometry, dissolution testing 
apparatus, and so on. 
Because of the cost and limited availability of MQCL, investigations are generally limited 
to relatively isolated and high-cost surveys and spot checking by large procurement agencies 
at or before the level of importation (missing the possibility of later substitution within the 
supply chain).
9
 Hence, there is a need for low-cost, robust, handheld devices for use as 
screening tools to detect poor-quality medicines with ease throughout the supply chain. 
Ideally, such a method would also be nondestructive. Devices fitting these criteria could 
transform pharmaceutical supply lines, providing assurance to health services, local 
providers, and consumers, while damaging the profitability of the drug counterfeit industry.
10
 
Nondestructive spectroscopic techniques such as Raman spectroscopy and near-infrared 
spectroscopy (NIRS) are gaining interest for their ability to test drug samples without using 
the toxic chemicals or flammable solvents typically used in a MQCL, and with low training 
requirements.
11
 Raman and NIRS are limited to analyzing the state of the surface presented to 
the detector. Both techniques rely on comparing the characteristic spectral “fingerprint” of a 
suspect medicine with a quality-assured sample. To distinguish falsified from quality-assured 
medicines necessitates access to a database of spectra containing the spectral signature of the 
quality-assured product. NIRS, in particular, requires relatively complex computer analysis 
for library comparisons, as spectral features in this wavelength range are less pronounced 
than those observed by mid-infrared and Raman spectroscopy. Using NIRS to detect 
subtherapeutic levels of SAPIs necessitates that the specific chemical signature be 
distinguishable and quantifiable within the spectral pattern, and the surface presented be 
representative of the quantity within the whole product. 
The TruScan
®
 by Thermo Fisher Scientific has been investigated for drug-quality 
application in field settings and is equipped with software to identify certain artemisinin 
derivatives.
12–14
 However, adapting the TruScan as well as the UV-Vis-NIR devices for the 
identification of falsified medicines in field settings has been limited.
15
 Portable Raman 
spectrometers are available for purchase for approximately USD 17,000–50,000, with costs 
driven by their relatively complex optics and necessity for a high-intensity illumination 
source.
11
 NIRS systems are simpler, requiring only a lamp for illumination and a dispersive 
optic, and are therefore more amenable to portability and low cost (approximately USD 
1,000). 
Herein, we evaluate the usefulness of a consumer NIRS technology presently marketed at 
USD 250 (“SCiO” research model device, Consumer physics, Israel), for its potential to 
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detect poor-quality (substandard and falsified) first-line antimalarial medicines, specifically 
artemisinin-based combination therapies (ACTs). The ACTs used had been purchased in 
Bioko Island, Equatorial Guinea, and Kintampo, Ghana, and previously undergone quality 
testing. 
MATERIALS AND METHODS 
The NIRS device. 
The Consumer Physics SCiO research model NIRS device used in this study is a 
smartphone-sized instrument that promises to be highly effective at checking the quality of 
medications in the absence of a MQCL. It operates as a diffuse reflectance NIR spectrometer 
and includes a small, optical integrating attachment similar to an integrating sphere (Figure 
1). The device used in this work, a research prototype, was operated using a smartphone app. 
Field samples. 
Artemisinin derivative-containing antimalarials, including ACTs and monotherapies, 
were purchased in Bioko Island, Equatorial Guinea. A total of 677 samples (77 brands) were 
purchased using three different systematic sampling approaches (convenience, mystery, and 
overt) from 278 outlets comprising of pharmacies, patent medicine vendors, public health 
facilities, and private hospitals (publication under review). 
Samples were analyzed for content using the gold standard method of HPLC-PDA to 
quantify the amount of SAPIs present in each sample (SAPI 1 = artemisinin derivative, SAPI 
2 = nonartemisinin antimalarial partner drug). Results were expressed as a percentage of the 
SAPI indicated on the packaging and samples were classified as quality assured, substandard, 
degraded, or falsified. The analysis showed that 7.4% of the samples were falsified, 1.6% 
were substandard, and 91.0% were quality assured. No degraded samples were detected 
(manuscript for publication in preparation). 
Similarly, 257 artemisinin derivative-containing samples (31 brands) were purchased in 
Kintampo, Ghana, using the mystery client sample collecting approach. Analysis using the 
HPLC-PDA found 37.0% of the samples were substandard and 63.0% samples were quality 
assured. Quality-assured samples were so classified when they contained SAPIs within the 
tolerance band of 85–115% as measured by HPLC-PDA analysis and those out of this range 
were classified as substandard. The acceptable range for artemisinin-containing antimalarial 
(ACA) and its companion drugs according to the international pharmacopeia is for it to 
contain 90.0–110.0% SAPIs. However, the wider tolerance band was selected by the ACTc-
DQ team to reflect the typically observed experimental variation in HPLC laboratory testing 
where less than 10 samples of each ACA formulation were tested.
7
 No falsified or degraded 
samples were detected.
16
 
NIRS spectrum acquisition. 
Sample brands (Table 1) from Bioko Island, Equatorial Guinea, and Kintampo, Ghana, 
already analyzed for quality using the gold standard technique of HPLC-PDA were used to 
validate the usefulness of the NIRS device. The HPLC results were not shared at this stage 
with the persons using the NIR, ensuring that the study was blinded at this stage. Each ACA 
sample tablet under investigation (677 from Bioko Island and 257 from Kintampo, Ghana) 
was placed in the integrator attachment of the NIRS and scanned three times. Triplicate 
scanning reduces signal-to-noise ratio (by averaging scans together) and enables for the 
consistency of scan quality to be assessed. Bilayer tablets (all of which were Winthrop
®
 
artesunate–amodiaquine formulations) were scanned three times on each side and the two 
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sides were considered independently for the analysis. The geometry of all the tested bilayer 
tablets was such that the two layers could be scanned separately using the integrating 
attachment. 
Measurements were carried out in the 740- to 1,060-nm wavelength range, which is the 
full range of the NIRS device. The acquisition time for a single spectrum was around 2 
seconds. The combination of the optical geometry of the integrating attachment and robust 
spectral preprocessing (described below) allowed spectra obtained with the integrating 
attachment to be consistent over a wide range of tablet positions within the chamber. 
In addition, reference standard compounds of artemether, lumefantrine, artesunate, 
amodiaquine, dihydroartemisinin, and piperaquine were scanned without the integrating 
attachment (it is not possible to place them in the integrating attachment without 
contaminating of the interior surfaces). 
Spectral processing. 
The goal of spectral processing is to remove extraneous signals such as background 
offsets and noise while enhancing spectral features. Averaged spectra were converted to 
absorbance units to enable linear fitting with reference standard compound in subsequent 
regression analysis. Spectra were then smoothed using a Savitzky–Golay filter, a common 
method that uses a sliding polynomial fit to reduce noise. For qualitative analysis, 
(identification) the second derivative spectra of absorbance were used to sharpen and enhance 
spectral features, a technique which produces improved performance in conjunction with 
library matching algorithms. For regression analysis of API concentration, the smoothed 
absorbance spectrum was used following a background subtraction. 
Analysis to identifying falsified samples. 
The primary goal of qualitative analysis was to distinguish quality assured from falsified 
medicines. This was achieved using a library matching algorithm composed of a binary 
acceptance threshold based on Mahalanobis distance. Mahalanobis distance is a 
multidimensional distance measure that accounts for the mean and covariance of a target 
cluster (in this case a drug class). This is similar to the standard or z-score of a Gaussian 
distribution in one dimension and it can be used as a simple and robust measure of whether a 
sample under test belongs to a target cluster. Falsified medicines were excluded from all 
training sets, and cross-validation for testing quality-assured medicines was performed by 
excluding the batch under test from the training set. Excluding falsified medicines from the 
training set makes the resulting classifier more robust in real-world use, as a falsified drug 
could have any composition, not just those represented in the sample set. 
Analysis to identifying substandard samples. 
The primary goal of regression analysis was to identify substandard medicines. Herein, 
three methods were used including a quantitative neural network, principal components 
regression, and partial least squares regression (PLSR). Of these three, PLSR showed the best 
results with the least tendency for overfitting. All quantitative results were obtained using 
leave-one-out cross-validation, or to predict the concentration of each sample a unique 
calibration curve was produced that did not include data from that sample. 
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RESULTS AND DISCUSSION 
Reference standard compounds versus ACTs. 
NIR spectral analysis results of samples from Bioko Island were compared with those of 
the corresponding reference standard compound (Figure 2). Note that formulations of 
artesunate–amodiaquine are shown as separate spectra despite being part of the same 
combination therapy, as these compounds (artesunate and amodiaquine salt) are unstable 
together, which necessitates for them to be formulated either as two separate tablets or as 
separate layers of a bilayer tablet.
17,18
 Figure 2C shows the combined spectra for both bilayer 
and multi-tablet therapies. 
The spectral signatures shown in Figure 2A represent 12 brands of artemether–
lumefantrine, whereas Figure 2C represents 16 brands containing artesunate and eight brands 
containing amodiaquine (see Table 1). The relatively narrow error bars represented in these 
plots indicate that the NIR signatures of drugs containing the same SAPI are consistent across 
different brands, whereas drugs containing different SAPIs have NIR signatures distinct from 
each other. 
Spectral match of NIR peaks of the reference standard compounds and those from the 
samples of ACTs is shown for artemether–lumefantrine and artesunate (Figure 2A and C). 
However, this is not the case for peaks of amodiaquine, dihydroartemisinin, and piperaquine 
and tablets containing these medicines. This implies that a consistent formulation of 
excipients also contributes to the unique NIR spectral features associated with the SAPIs of 
the formulation as seen in Figure 2. 
Quality-assured formulations of artesunate–sulfamethoxypyrazine–pyrimethamine 
combination therapy were also tested in the Bioko Island sample set to determine the 
representative spectrum (Figure 2D). Although there were no falsified samples or reference 
standards to show spectral comparisons, the pronounced spectral features of this formulation 
made it easy to identify versus all other formulations. 
Detection of falsified medicines. 
The library matching algorithm described in the section analysis to identifying falsified 
samples was used to demonstrate the ability of a simple classifier to distinguish NIR spectra 
of quality-assured Coartem
®
 from falsified Coartem samples (Figure 3). The NIR spectrum of 
quality-assured Coartem is reproducible when compared with the falsified samples. This 
consistency in tablet spectra is most likely due to Coartem being produced by a manufacturer 
with WHO prequalification status. The Coartem cluster in Figure 3B (blue) contains 23 
batches of quality-assured Coartem from two manufacturing locations (United States and 
China). Unsurprisingly, the library matching algorithm was able to distinguish quality 
assured from falsified Coartem with complete (100%) accuracy. 
Artemisinin-based monotherapy tablets are not recommended for the treatment of malaria 
by WHO, but were purchased in Bioko Island. The library matching algorithm used was able 
to distinguish between the falsified and quality-assured monotherapy tablets (Table 2). 
Detection of substandard medicines. 
Substandard medicines (i.e., low API concentrations), samples purchased in Kintampo, 
Ghana, that had been analyzed with HPLC-PDA and classified as substandard were used to 
assess the ability of NIRS to identify them (Table 3). Regression analysis of the NIRS spectra 
could not indicate the quantity of amodiaquine in the Arsuamoon
®
 brand (Figure 4), as the 
spectra of the reference standard amodiaquine was not distinguishable in the spectral 
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signature of therapies containing amodiaquine (Figure 2). In contrast, changes in the 
concentration of artesunate in the Combicure Adult brand (where artesunate and amodiaquine 
are formulated as separate tablets) could be detected, although the accuracy was low (R
2
 = 
0.66). The Combicure Adult sample set had artesunate concentrations determined using 
HPLC-PDA ranging from 74.8% to 103% of SAPI, corresponding to doses of 74.8–103.0 
mg. The quantitation accuracy of this linear model is defined by the standard deviation of the 
normalized residuals, which was 7.4%. This indicates that the NIRS can quantify the SAPI 
within 14.8% with 95% certainty. However, the sample number was relatively low in this 
regression (N = 15) and a larger sample size is needed to determine the significance of this 
result. Figure 4A and B show the spectra of the two artesunate–amodiaquine brands, 
Combicure Adult and Arsumoon. Note that the spectra of Combicure Adult indicated 
systematic variation with SAPI concentration (shown by different colors), whereas the 
spectra of Arsuamoon does not. 
CONCLUSION 
Falsified and substandard medicines are a major contributor to morbidity and mortality 
through treatment failure. The lack of a low-cost, simple, and reliable testing method to 
assess quality on the ground has restricted the ability of health and enforcement authorities to 
detect and deal with this issue. The results presented here indicate that handheld NIRS 
devices offer promise to address at least the first of these problems, that is, detecting falsified 
products provided that a consistent spectrum from the quality-assured product is available for 
comparison. NIRS also showed potential for detecting certain medicines with insufficient 
concentration of the SAPI and hence could be used for identifying substandard medicines, 
though we were only able to test the Combicure Adult and Arsumoon brands. These results 
require further validation and indicate that quantitation may not be possible for certain SAPIs, 
such as amodiaquine. Access to a wider NIR wavelength range of 740–1,060 nm will 
improve the detection of varying amounts of SAPIs. Handheld NIR spectrometers with 
wavelength ranges up to 2,400 nm are now available for sale. 
The NIRS, coupled with the appropriate spectral library proved effective for identifying 
falsified samples of Coartem (artemether–lumefantrine) across multiple batches and 
manufacturing locations. Based on these results and the underlying technology, it seems 
likely that handheld NIRS scanners would be highly effective instruments for screening 
medicines from well-characterized brands with high-quality manufacturing (Coartem is 
prequalified by WHO). Falsified samples of other formulations or brands with matched 
quality-assured samples were only available for artesunate monotherapies. 
The development of a library of spectra of quality-assured products approved by a 
national regulatory authority would allow low-cost rapid testing at port of entry and 
throughout the supply chain, as well as offer health providers and consumers with a means to 
confirm the authenticity of the product at point of use. Although technical developments in 
the near future are likely to enlarge this further, capacity to detect substitution of falsified 
products into supply chains should now be available to health systems and monitoring 
services with currently available technology. 
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FIGURE 1. Photograph of the Consumer Physics near-infrared spectrometer (NIRS) research model. This image 
shows the (A) integrating attachment, (B) NIRS spectrometer, and (C) location of the light source and sensor on 
the NIRS. A dose of Lumartem
®
 is shown for scale. This figure appears at  appear at www.ajtmh.org. 
FIGURE 2. Second derivative absorption spectra of different active pharmaceutical ingredient (API) groups 
matched with the spectra of the associated API standards, when available. Artesunate–amodiaquine is a 
combination therapy in which the two stated active pharmaceutical ingredients are formulated as either a bilayer 
or as separate tablets. This allowed their spectra to be collected and presented separately. The spectra in (C) 
represent scans from both bilayer tablet and multi-tablet doses. This figure appears at appear at www.ajtmh.org. 
FIGURE 3. (A) Second derivative near-infrared spectra of quality assured and falsified Coartem. (B) Principal 
components clustering diagram for the spectra in (A). This figure appears at  appear at www.ajtmh.org. 
FIGURE 4. (A–B) Absorbance spectra of (A) amodiaquine tablets of Arsuamoon and (B) artesunate tablets of 
Combicure Adult. Concentration is indicated by color. (C) Results of partial least squares regression for 
amodiaquine in Arsuamoon and (D) artesunate in Combicure Adult. Concentrations are shown as a percentage 
of the labeled concentration. R
2
 values are 0.02 for (C) and 0.66 for (D). Fittings were based on three partial 
least squares modes. This figure appears at  appear at www.ajtmh.org. 
TABLE 1 
Formulations of antimalarial medicines of varying brands and manufacturers tested using NIR spectroscopy 
SAPI Brand name Manufacturer Country 
Artemether–lumefantrine 
Alu Ipca India 
Artefan Ajanta India 
Artemef Cipla India 
Coartem Novartis 
China and United 
States 
Coatal Jiangsu Yixing China 
Cofantrine Bliss GVS India 
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Colart Ipca India 
Combisunate Ajanta India 
Lonart-Ds Bliss GVS India 
Lufanter Bliss GVS India 
Lumartem/LumArt + Cipla India 
Tamether Fort Jiangsu Yixing China 
Artesunate monotherapy 
Actitesunate Jiangsu China 
Adamsnate Adams China 
Artesunat Mekophar Vietnam 
Artesunate 50 Aurochem India 
Artesunate Tabs Guilin China 
Cusnat Artesunate Green Energy China 
Gricin Greenfield Chain 
Lever Artesunate Adams China 
Artesunate–amodiaquine 
Adamsnate Plus Adams China 
Arsuamoon Guilin China 
Art Amo Adult Ipca India 
ArtAm Guilin China 
Arthesis + Cipla India 
Asaq-Denk Artesan Germany 
Malatex Kinapharma Ghana 
Winthrop Maphar Morocco 
Artesunate–sulfamethoxypyrazine–
pyrimethamine 
Co-Arinate Famar Italia Italy 
Malafan Plus Kinapharma Ghana 
Dihydroartemisinin–piperaquine Waipa Act Kunimed Nigeria 
NIR = near-infrared; SAPI = stated active pharmaceutical ingredient. 
TABLE 2 
Falsified drug identification sample set and results 
Brand 
name 
SAPIs 
Quality assured Falsified  
WHO 
PQ? 
Samples 
Country of 
manufacture (no. of 
batches) 
Samples Batches Sens/spec 
Coartem 
Artemether 
Lumefantrine 
Yes 60 
United States (15) 
China (8) 
22 3 100/100 
Artesunat Artesunate No 3 Vietnam (1) 19 2 100/100 
Cusnat Artesunate No 36 China (2) 1 1 100/100 
SAPI = stated active pharmaceutical ingredients; sens/spec = sensitivity/specificity; WHO PQ = World Health 
Organization prequalified (manufacturer). 
TABLE 3 
Sample set for determining API concentration 
Brand API group 
Substandard 
component 
API range 
(%) 
Samples Batches WHO PQ? 
Arsuamoon 
Artesunate–
amodiaquine 
Amodiaquine 66–85 15 7 Yes 
Combicure 
Adult 
Artesunate–
amodiaquine 
Artesunate 75–83 10 4 No 
API = active pharmaceutical ingredient; WHO PQ = World Health Organization prequalified (manufacturer). 
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